TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32139212
Drug: RHB-102 (24-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: RHB-102 (24-mg bimodal-release ondansetron)
Study: 32215727
Drug: Drug plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug plus psychotherapy (DPP) with olanzapine and metacognitive training (MCT) for 8 weeks
Study: 32215727
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (DT) with olanzapine for 8 weeks
Study: 32215727
Drug: Drug plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug plus psychotherapy (DPP) with olanzapine and MCT
Study: 32215727
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (DT) with olanzapine
Study: 34034273
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG + 290 µg linaclotide (2 L PEG + L group)
Study: 34034273
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG
Study: 33644749
Drug: Combination training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination training
Study: 33980234
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) with metronidazole (MET) and oral hygiene instructions (OHI)
Study: 33980234
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions (OHI) only
Study: 32195649
Drug: Iclaprim 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclaprim 80 mg
Study: 32195649
Drug: Vancomycin 15
Normalized name: vancomycin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15 mg/kg administered intravenously every 12 hours for 5-14 days
Study: 35212648
Drug: Inhaled lavender
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled lavender essence (diluted with sweet almond oil at a ratio of 1:10) administered before cannulation during 12 HD sessions.
Study: 33610374
Drug: IIV4-HD 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4-HD 60 µg
Study: 33610374
Drug: IIV4-SD (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4-SD (15 µg HA/strain)
Study: 35343725
Drug: Relaxation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation group therapy (RGT)
Study: 32991788
Drug: Aripiprazole (ARI)
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole (ARI) 10 mg
Study: 32991788
Drug: Olanzapine (OLA)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (OLA) 5 mg
Study: 32205684
Drug: Epidural Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural Fentanyl and Bupivacaine (10-mL solution of 50 mcg of Fentanyl, 0.125% Bupivacaine, and 0.9% saline solution)
Study: 32628554
Drug: Low-Dose Rivaroxaban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Rivaroxaban plus Aspirin
Study: 32960053
Drug: BAY 1214784,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1214784, an orally available spiroindoline derivative, administered once daily
Study: 32996592
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with telapristone acetate (12 mg/day)
Study: 32609979
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for 5 days
Study: 33735146
Drug: MUSTCOOL cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: MUSTCOOL cooling patch
Study: 36289399
Drug: Bamlanivimab 7,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamlanivimab 7,000 mg
Study: 35002538
Drug: Wrist-ankle acupuncture-moxibustion
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist-ankle acupuncture-moxibustion and hot compression with Chinese herbal medicine
Study: 32532310
Drug: Ropivacaine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 75 mg
Study: 35999521
Drug: Flash dose
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flash dose of preoperative corticosteroids
Study: 32641470
Drug: Naproxen (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (both doses)
Study: 35713449
Drug: Nalbuphine in
Normalized name: nalbuphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine in patient-controlled intravenous analgesia
Study: 32427667
Drug: Social support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social support for overcoming treatment-related challenges
Study: 32887707
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump therapy (SAP) for 1 year
Study: 32887707
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (multiple daily injection therapy)
Study: 36241128
Drug: eRAPID (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: eRAPID (weekly online symptom reporting for 12, 18 & 24 weeks)
Study: 34319247
Drug: SMS text
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS text messaging intervention (daily for the first 4 weeks, 5 messages on week 5, 3 messages each in weeks 6 and 7, and 1 message weekly from week 8 to week 52)
Study: 34319247
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly SMS text message reminding of next study appointment and importance of the study)
Study: 33664081
Drug: 3.375‐4.5 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.375‐4.5 g intravenous piperacillin‐tazobactam
Study: 33664081
Drug: 1‐2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐2 g intravenous cefoxitin
Study: 32815891
Drug: Telephone-based administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based administration of the ABILHAND
Study: 32815891
Drug: Face-to-face administration
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face administration of the ABILHAND
Study: 34168029
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) - single dose of 40 mg/kg
Study: 32698957
Drug: Synbiotic supplement
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplement (109 CFU/day) for 8 weeks
Study: 34842215
Drug: Integral Meditation
Normalized name: Meditize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integral Meditation (IM) program consisting of 12 weekly meditation classes after the afternoon shift
Study: 32605509
Drug: Lung cancer
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung cancer screening with low-dose computed tomography
Study: 32683992
Drug: Home exercises
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercises (10 min daily for 3 weeks)
Study: 32155018
Drug: Topical combination
Normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical combination therapy with 5% imiquimod cream, 2% 5-FU solution, and 0.1% tretinoin cream, applied five nights per week under occlusion for a treatment goal of 30 total applications.
Study: 32576275
Drug: Residential behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential behavior therapeutic smoking cessation therapy
Study: 32576275
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient behavior therapeutic smoking cessation group therapy
Study: 35154550
Drug: Hydromorphone group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone group (spinal anesthesia with 0.5% ropivacaine and 75 μg hydromorphone)
Study: 35154550
Drug: Morphine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine group (spinal anesthesia with 0.5% ropivacaine and 150 μg morphine)
Study: 33209056
Drug: Morphine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine group
Study: 33582693
Drug: Standard Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Triple Drug Therapy
Study: 33582693
Drug: Sequential Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Drug Therapy
Study: 35108620
Drug: Brief hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief hypnotic induction with reduced preoperative local anesthetics (Dave Elman technique)
Study: 35108620
Drug: Regular preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular preoperative local anesthetics without brief hypnotic induction (standard care)
Study: 35108620
Drug: Brief hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief hypnotic induction
Study: 34644368
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low carbohydrate diet (VLCBD) (<20g daily intake)
Study: 39475399
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (control group)
Study: 36038516
Drug: Multifunctional laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifunctional laser photoelectric platform combined with hydroxychloroquine (0.2 g, twice a day)
Study: 36038516
Drug: Hydroxychloroquine sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulfate tablets (0.2 g, twice a day)
Study: 35429850
Drug: Bilateral GNB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral GNB with 0.125% bupivacaine, 0.5 xylocaine, and 4 mg dexamethasone
Study: 34256820
Drug: Increased maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased maternal speech exposure (treatment group, n = 21)
Study: 32543161
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (2 ml, 0.25 mg/ml suspension for nebulizer) administered within 6 hours of birth and a second dose 12 hours later.
Study: 32543161
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation (2 ml of distilled sterile water).
Study: 35232482
Drug: Chiropractic care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic care (CC)
Study: 34818400
Drug: CAF +
Normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAF + L-PRF
Study: 32943239
Drug: Genetically predicted
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically predicted an extra daily cup of tea consumption
Study: 34921756
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg/day for 35 days
Study: 33499679
Drug: Sugammadex calculated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex calculated using corrected body weight (CBW), 4 mg/kg
Study: 33499679
Drug: Sugammadex calculated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex calculated using total body weight (TBW), 4 mg/kg
Study: 34193056
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg/daily
Study: 32108022
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and statins (oral drugs)
Study: 36013137
Drug: Gentle Touch
Normalized name: Gentle Touch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentle Touch Therapy (GTT)
Study: 35259147
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (synchronized radiofrequency and HIFEM)
Study: 33687872
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral anticoagulation (OAC) with direct oral anticoagulants (DOACs)
Study: 33599431
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1000 mg daily for 8 weeks)
Study: 33599431
Drug: Medium chain
Normalized name: Medium chain triglyceride
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium chain triglyceride (1000 mg daily for 8 weeks)
Study: 35489044
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (customary treatment)
Study: 34503367
Drug: IM20-4 (20μg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM20-4 (20μg, 4 doses)
Study: 34503367
Drug: IM60-4 (60μg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM60-4 (60μg, 4 doses)
Study: 34503367
Drug: Short-term high-strength
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term high-strength vaccination group (4 doses)
Study: 34503367
Drug: Standard vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vaccination group (3 doses)
Study: 33451954
Drug: Esmolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1 mg/kg as a bolus before aortic cross‐clamping and 2 mg/kg mixed in the cardioplegia solution)
Study: 32138631
Drug: EG-1962 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG-1962 (600 mg intraventricular dose)
Study: 32138631
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral nimodipine)
Study: 36749631
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonism
Study: 34391812
Drug: 0.9% spinosad
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% spinosad topical suspension
Study: 33179988
Drug: QSPR modelling
Approvals — FDA: no, EMA: no, PMDA: no
Description: QSPR modelling of aliphatic compounds
Study: 33179988
Drug: QSPR modelling
Approvals — FDA: no, EMA: no, PMDA: no
Description: QSPR modelling of phenyl‐based compounds
Study: 35422053
Drug: Oral-transmucosal haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-transmucosal haloperidol 2.5 mg
Study: 35422053
Drug: Oral-transmucosal olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-transmucosal olanzapine 5 mg
Study: 32293657
Drug: Conventional wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional wound treatment (CWT)
Study: 36056388
Drug: Personalised intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalised intervention programme including modules such as Brief messaging, Clinical medication review, Medication schedule, Reminding messaging, Medication dispensing systems, Smart messaging, Referral to general practitioner, Unguided web-based Self Help Application for low mood.
Study: 33707410
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (weekly sessions from January 22 to March 11, 2020)
Study: 35964417
Drug: Amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (10 or 20 mg)
Study: 35964417
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 or 400 mg)
Study: 32496448
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (gDT)
Study: 34836275
Drug: Vinegar group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinegar group (1.5 g acetic acid/day as liquid vinegar)
Study: 34836275
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.015 g acetic acid/day as a pill)
Study: 35385090
Drug: PARS intervention
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PARS intervention (1-session secondary prevention module administered by trained SUD counselors)
Study: 33564993
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine and morphine (ITBM) group, n = 45
Study: 32233962
Drug: Obstetrician-gynecologists retrieving
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstetrician-gynecologists retrieving medication safety information during clinical visits
Study: 33010968
Drug: Multimodal pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal pelvic floor physical therapy (12 weekly 60‐min sessions)
Study: 33010968
Drug: Multimodal pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal pelvic floor physical therapy
Study: 33117131
Drug: 10 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Hz rTMS treatment
Study: 33117131
Drug: No-stim control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-stim control treatment
Study: 33567218
Drug: Violet light-emitting
Normalized name: Gentian Violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Violet light-emitting diodes (LEDs) device emitting violet light (405-410 nm) without peroxide-containing bleaching gel
Study: 35346348
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual + DIALOG scale
Study: 35702866
Drug: Hypothetical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical therapy improvements in silico
Study: 33037726
Drug: Nifekalant 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifekalant 0.4 mg/kg
Study: 33037726
Drug: Nifekalant 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifekalant 0.5 mg/kg
Study: 33037726
Drug: Nifekalant 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifekalant 0.3 mg/kg
Study: 36055874
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg FMP013 / 0.5 mL ALFQ (Low dose group)
Study: 36055874
Drug: 40 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg FMP013 / 1.0 mL ALFQ (High dose group)
Study: 36125053
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (2g daily for 6 weeks)
Study: 35169169
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (200 mL single transfusion)
Study: 32134882
Drug: PowerPoint-based e-CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PowerPoint-based e-CBT delivered via email (12 weekly modules and homework assignments)
Study: 35973787
Drug: Optimised standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised standard medical therapy (SMT)
Study: 32735053
Drug: 16-week smartphone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-week smartphone-based aftercare intervention with therapist feedback as add-on to treatment as usual (TAU)
Study: 33258495
Drug: Daily chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chlorhexidine showers and mupirocin nasal ointment twice a day for 5 days before surgery (S. aureus carrier group)
Study: 33258495
Drug: Daily chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chlorhexidine showers (noncarrier group)
Study: 36347059
Drug: Oral combination
Normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combination regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) for 24 weeks
Study: 36347059
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment of anal high-grade squamous intraepithelial lesions
Study: 32696227
Drug: Intravenous 5%
Normalized name: immune globulin intravenous 5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5% dextrose in 0.9% normal saline (according to weight-based maintenance rate)
Study: 32696227
Drug: Dexamethasone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.15 mg·kg−1 iv) and ondansetron (0.05 mg·kg−1 iv)
Study: 35386725
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received the same anesthetic drugs
Study: 32126977
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg oral daily for 6 months
Study: 32126977
Drug: IFN-β 1b
Normalized name: IFN-gamma 1b
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-β 1b 250 μg subcutaneous every other day for 6 months
Study: 34371162
Drug: ALED program
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALED program in combination with Our Voice (neighborhood-level citizen science intervention)
Study: 32077891
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks) starting 2 to 6 weeks after chemoradiotherapy
Study: 32077891
Drug: Pembrolizumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (100 mg IV every 3 weeks) starting day 29 of chemoradiotherapy
Study: 32077891
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks) starting day 29 of chemoradiotherapy
Study: 32077891
Drug: Pembrolizumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (100 mg IV every 3 weeks) starting day 1 of chemoradiotherapy
Study: 32077891
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks) starting day 1 of chemoradiotherapy
Study: 32077891
Drug: Pembrolizumab (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (at least 1 dose)
Study: 32077891
Drug: Pembrolizumab (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (at least 2 doses)
Study: 35468266
Drug: Group-based outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based outpatient physical therapy intervention delivered six weeks after TKR.
Study: 33999707
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dronabinol
Study: 35857131
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg kg−1)
Study: 32816639
Drug: Buspirone (7.5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (7.5-15 mg twice daily)